TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04061876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants began oral administration of ruxolitinib at 5 mg QD;Methylprednisolone: 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 3 days, then taper according to the clinical response. 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 3 days, then taper according to the clinical response. 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
Study: NCT03232918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half dose Oxytocin
Description: Patients randomized to the half dose oxytocin group will have the oxytocin infusion reduced to 50 % prior to placement of combined spinal epidural for labor analgesia
Study: NCT06256081

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hear Glue ear application
Description: Hear Glue ear is an application used on phones, ipads, tablets or computers which provides free information, songs, audiobooks, games and a home hearing screening game.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hear Glue ear application
Description: Hear Glue ear is an application used on phones, ipads, tablets or computers which provides free information, songs, audiobooks, games and a home hearing screening game.
Study: NCT03478449

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node sorting for pathological examination
Description: In this study, intervention methods include two kinds of lymph node sorting for pathological examination in gastric cancer samples after curative surgery. One is the fine sorting lymph nodes, representing the lymph nodes should be sorted one by one from the tissues around the stomach, celiac axis, and the main brunches of celiac axis. The other is the group sorting lymph nodes, representing the lymph nodes should be simply sorted in the soft tissues around the stomach, celiac axis, and the main brunches of celiac axis.
Study: NCT04848324

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Hydrodissection
Description: The median nerve was examined by US at the scaphoid-pisiform level of the inlet of carpal tunnel. The hydrodissection was achieved by a total volume of 3 mL (1 mL of triamcinolone and 2 mL of saline) in the intervention group based on a study identifying median nerve hydrodissection with this volume. Half of the total volume (1.5 mL ) was delivered via the in-plane ulnar approach and the other half (1.5 mL) via the in-plane median approach to create a fluid plane along the nerve.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: 1 mL of triamcinolone was delivered via the in-plane ulnar approach
Study: NCT02042027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamunex-C
Description: Patients will receive 50 mg (0.5 mL) subconjunctival Gamunex-C injection in addition to standard of care treatment (steroids and cyclosporine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamunex-C
Description: Patients will receive 50 mg (0.5 mL) subconjunctival Gamunex-C injection in addition to standard of care treatment (steroids and cyclosporine)
Study: NCT01375998

Intervention type: DRUG
Intervention: EE20/DRSP(YAZ, BAY86-5300)
Description: Patients in daily life treatment receiving YAZ for dysmenorrhea.
Study: NCT05431218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol Liquid
Description: daily single dose of the drug in the first half of the day in an individually selected dose for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol Liquid
Description: daily single dose of the drug in the first half of the day in an individually selected dose for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol Liquid
Description: daily single dose of the drug in the first half of the day in an individually selected dose for 3 months
Study: NCT00605332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inferior vena cava filter
Description: Crux Biomedical IVC Filter
Study: NCT02833324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education regarding ambulation
Description: The participants will be educated on the importance of postoperative ambulation during the recovery period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education regarding ambulation
Description: The participants will be educated on the importance of postoperative ambulation during the recovery period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulation reminder alarms
Description: Participants in the intervention arm will receive 5 daily alarms to prompt them to ambulate. Alarms will be set to ring at 9am, 11am, 2pm, 5pm and 9pm. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants who are postoperative for colorectal surgery, who have been cleared to ambulate during recover, will be equipped with an off-the-shelf Fitbit device (a wireless activity tracking device) which will record steps taken while the participant is hospitalized. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Participants who are postoperative for colorectal surgery, who have been cleared to ambulate during recover, will be equipped with an off-the-shelf Fitbit device (a wireless activity tracking device) which will record steps taken while the participant is hospitalized. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
Study: NCT03290053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: SonoVue-infusion over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: SonoVue-infusion over 1 hour

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium chloride
Description: Placebo

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium chloride
Description: Placebo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound
Description: Transcranial ultrasound aimed at the blockage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound
Description: Transcranial ultrasound aimed at the blockage

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Ultrasound
Description: Placebo - machine is attached, but not active

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Ultrasound
Description: Placebo - machine is attached, but not active
Study: NCT04659330

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online education (BdandMe) for injection technique
Description: patients were referred to the relevant modules on BD and Me™ (for online education)

Intervention type: DEVICE
Group type: OTHER
Intervention: 4mm needles
Description: Providing a supply of needles for single use of 4mm insulin injection needle.
Study: NCT01860326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Capsules supplied as open labeled bulk medication in 10-unit blister packages
Study: NCT03869177

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation support program
Description: The IFIP intervention consists of the following elements:~I. Clinical interventions 1.1 A basic level of family involvement and support 1.2 Family psychoeducation in single-family groups~II. Implementation interventions 2.1 Training and guidance of health care personnel 2.2 A family coordinator 2.3 Other implementation measures
Study: NCT01777165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-719
Description: 1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-719
Description: 1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-719
Description: 1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion
Study: NCT02118649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game
Study: NCT00154687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin, 5-Fluorouracil
Study: NCT03618199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efficacy of transcranial vibrating system on mitigating dizziness and nausea during caloric testing
Description: Transcranial vibrating system will be on then off (or off then on in a random order) during a repeated application of the calorics testingstimulus, i.e. warm or cold water irrigated in the left (then right) ear canal. The effect of the vibrating system on 1) resulting dizziness and nausea often experienced by patients and 2) clinical parameters measured by caloric testing will be quantified.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efficacy of transcranial vibrating system on mitigating dizziness and nausea during caloric testing
Description: Transcranial vibrating system will be on then off (or off then on in a random order) during a repeated application of the calorics testingstimulus, i.e. warm or cold water irrigated in the left (then right) ear canal. The effect of the vibrating system on 1) resulting dizziness and nausea often experienced by patients and 2) clinical parameters measured by caloric testing will be quantified.
Study: NCT02461004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-391
Description: Investigational product is prescribed to all of radomized subjects for two times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-391
Description: Investigational product is prescribed to all of radomized subjects for two times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovastatin and Ezetimibe combination therapy
Description: Investigational products are prescribed to all of radomized subjects for two times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovastatin and Ezetimibe combination therapy
Description: Investigational products are prescribed to all of radomized subjects for two times.
Study: NCT01428427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Continuous daily oral dosing while on study or disease progression (cycle = 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dosing once weekly for 3 weeks in a 28 day cycle until disease progression.
Study: NCT02708381

Intervention type: OTHER
Intervention: Screening
Description: Screening for geriatric issues to be referred to the Moffitt Cancer Center Oncogeriatric Information Team (OGIT).
Study: NCT01823705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exilis Implantable Gastric Electrical Stimulation (GES)
Study: NCT02952521

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: CA125 and ctDNA

Intervention type: PROCEDURE
Intervention: Tumor Tissue Biopsy
Description: Only collected at time of surgery if patient undergoes surgical debulking
Study: NCT00505154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 10 mg tablets od for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03766776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib capsules: dosage of 12 mg PO qd, 14 days, 7 days, 21 days for a cycle. The dosage was adjusted according to the adverse reactions of patients.
Study: NCT04477395

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: SRP will be supplemented with the dietary fish oil rich in omega-3 PUFAs EPA and DHA for 6 months. Fish oil (BioMarine Medical, 200 ml liquid), obtained from Tasmanian deep sea shark and Norwegian cod liver and sardine, anchovy and mackerel muscle, will be administered two times a day at a dose 10 ml. Daily dose of 20 ml provides 2.6 g of EPA and 1.8 g of DHA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP only
Description: Scaling and root planing will be the only method of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP only
Description: Scaling and root planing will be the only method of treatment.
Study: NCT00441259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax™-JE
Description: One dose of 4.0 log10 PFU is given in a volume of 1 ml for children aged \> 3 years and 0.5 ml to children and infants aged \< 3 years administered subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis Inactivated Mouse Brain Vaccine
Description: Two doses of 1 ml reconstituted JE-MBDV is given to subjects aged \> 3 years and 0.5 ml is given to children and infants aged \< 3 years administered subcutaneously
Study: NCT01098916

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Home X-rays
Description: X-rays examinations performed at home

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: X-rays in hospital
Study: NCT01162486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin & midazolam
Description: rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine & midazolam
Description: rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine & midazolam
Description: rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine & midazolam
Description: rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine and midazolam
Description: rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine and midazolam
Description: rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
Study: NCT01305408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil tablets, taken orally, once daily in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets, taken orally, once daily in the morning
Study: NCT03513705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best practices in pancreatic cancer care
Description: All best practices follow the current state of the Dutch guideline on pancreatic cancer and the literature.
Study: NCT04439045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002
Description: VPM1002 is a recombinant BCG (rBCG)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study: NCT04277884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firibastat
Description: Oral administration 2×250 mg capsules bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration 2 capsules bid
Study: NCT03834025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2 Condition 2
Description: Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 30% of the NC Medicaid rate for a patient visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2 Condition 2
Description: Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 30% of the NC Medicaid rate for a patient visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2 Condition 2
Description: Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 30% of the NC Medicaid rate for a patient visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2 Condition 3
Description: Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 100 percent of the NC Medicaid rate for a patient visit for their time participating in the learning collaborative.
Study: NCT01682265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretta procedure

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: No radiofrequency delivered
Study: NCT00521157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Go Medical Naltrexone implants
Description: Naltrexone implants 3.2 g (double of 1,6 g)
Study: NCT02866513

Intervention type: OTHER
Group type: OTHER
Intervention: evaluate the variations of transpulmonary pressure during the use of APRV by clinicians.
Study: NCT03983967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immuncell-LC
Description: Activated T lymphocyte
Study: NCT02807272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Oral tablet
Study: NCT03834025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2 Condition 3
Description: Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 100 percent of the NC Medicaid rate for a patient visit for their time participating in the learning collaborative.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2 Condition 3
Description: Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 100 percent of the NC Medicaid rate for a patient visit for their time participating in the learning collaborative.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 2 Condition 3
Description: Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 100 percent of the NC Medicaid rate for a patient visit for their time participating in the learning collaborative.
Study: NCT00511173

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Warfarin Dose based on pharmacogenetics
Description: Warfarin dose adjustment will be based on the standard clinician dosing compared to the use of the pharmacogenetic base algorithm
Study: NCT06079749

Intervention type: PROCEDURE
Intervention: Simultaneous BTKA
Description: Simultaneous BTKA

Intervention type: PROCEDURE
Intervention: Staged BTKA
Description: Staged BTKA
Study: NCT03427151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPP-201101
Description: 200 mcg of IPP-201101 will be administered subcutaneously every 4 weeks for 24 weeks.
Study: NCT03586934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg
Description: Celecoxib Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Description: Celecoxib Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivicaine nerve block (injection)
Study: NCT01727856

Intervention type: DEVICE
Intervention: Rehabilitation Measurement Tool
Description: The Rehabilitation Measurement Tool represents a telerehabilitation tool for physical therapy.
Study: NCT02912312

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated RNI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo standard RNI
Study: NCT03212014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LSVT-BIG
Description: LSVT BIG can be delivered by a physical or occupational therapist. Treatment is administered in 16 sessions over a single month (four individual 60 minute sessions per week). This protocol was developed specifically to address the unique movement impairments for people with Parkinson disease. The protocol is both intensive and complex, with many repetitions of core movements that are used in daily living. This type of practice is necessary to optimize learning and carryover of your better movement into everyday life!

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POWER
Description: Power Rehabilitation(PR), a new resistance training regime, can improve in power and independence level of the elderly people. The first word of PR was in brief of Produce Outcome Worthwhile for the Elderly Rehabilitation (POWER)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rehabilitation
Description: traditional exercise models in currently clinical use